Cathie Wood acquired 7.03 Million Verve Therapeutics shares worth $92.7 Million. That's 0.56% of their equity portfolio (34th largest holding). The investor owns 8.39% of the outstanding Verve Therapeutics stock. The investor's estimated purchase price is $190 Million, resulting in a loss of 51%.
Cathie Wood, the brilliant mind behind ARK Invest , is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made ...
InvestorPlace, 5 months agoVerve Therapeutics is developing a CRISPR-based gene therapy for cardiovascular diseases. Click here for our take on VERN assets and stock prospects.
Seeking Alpha, 12 months ago